Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Share:

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2006, Vol. 11 ›› Issue (4): 458-463.

Previous Articles     Next Articles

Tolerability and pharmacokinetics of multiple-dose Ceftriaxone Sulbactam (4:1) injection in Chinese health volunteers

WANG Jin, XIAO Yong-hong, LU Yuan, KANG Zi-sheng, ZHANG Ming, LIANG Jun, LIU Yan, ZHANG Man, LI Tian-yun   

  1. Institute of Clinical Pharmacology, the First Hospital, Peking University, Beijing 100083, China
  • Received:2003-01-02 Revised:2006-02-27 Online:2006-04-26 Published:2020-12-08

Abstract: AIM: To evaluate the pharmacokinetics of multiple-dose Ceftriaxone/Sulbactam (4:1) injection in Chinese health volunteers.METHODS: The serum samples and urine samples of 12 healthy volunteers were collected after injecting 2.50 g Ceftriaxone/Sulbactam (4:1) injection for 7 days.RESULTS: All health volunteers were well tolerated.The pharmacokinetic parameters were calculated by DAS software.The average of Cmax was 202.60 ±26.31 mg·L -1, Cav was 60.65 ±8.85 mg·L -1, AUCss was 1455.68 ±212.41 mg·L -1 ·h, DF was 3.36 %, FI was 96.77 %.The 72 h cumulative urinary excretion rate of Ceftriaxone was 43.61 %±10.23 % and the 12 h cumulative urinary excretion rate of Sulbactam was 71.61 %±10.06 %.CONCLUSION: 2.50 g multiple-dose Ceftriaxone Sulbactam (4:1) injection is well tolerated in the health volunteers.According to the results of pharmacokinetic parameters, there is no pharmacokinetic change between the two drugs from the compound preparation, and there is no drug interaction between them.

Key words: Ceftriaxone/Sulbactam (4:1) injection, pharmacokinetics, HPLC, multiple-dose

CLC Number: